GlassScriptPhysician profile
Shashikanth Nagabandi
NPI 1932515558
$3,396.51
in general payments reported to CMS, 2019-2025
21 companies · $387 in 2025
The $387 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,648 · 2020: $619 · 2021: $477 · 2023: $29.71 · 2024: $236 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $652.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $467.70 | 2019-2025 | |
| Artivion, INC. | $464.29 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $386.44 | 2019-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $350.71 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.33 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $223.96 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $185.11 | 2019-2021 | |
| Lantheus Medical Imaging, INC. | $135.75 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $115.47 | 2019 | |
| Astellas Pharma US INC | $115.41 | 2019-2020 | |
| Amarin Pharma, INC. | $103.63 | 2019-2020 | |
| Medtronic Vascular, INC. | $86.29 | 2019-2020 | |
| Vifor Pharma, INC. | $86.15 | 2019 | |
| Pfizer INC. | $83.38 | 2023-2025 | |
| Atricure, INC. | $73.50 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $70.47 | 2020-2025 | Repatha |
| Regeneron Healthcare Solutions, INC. | $62.53 | 2019-2020 | |
| Cvrx, INC. | $46.66 | 2024-2025 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $44.82 | 2024 | Arcalyst |
| Boston Scientific Corporation | $27.51 | 2025 | Watchman Flx |
| Z-Medica, LLC | $24.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shashikanth Nagabandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.